Published in Psychoneuroendocrinology on October 01, 1978
A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. N Engl J Med (2000) 10.25
The role of childhood trauma in the neurobiology of mood and anxiety disorders: preclinical and clinical studies. Biol Psychiatry (2001) 7.80
Pituitary-adrenal and autonomic responses to stress in women after sexual and physical abuse in childhood. JAMA (2000) 7.21
The relationship of depression to cardiovascular disease: epidemiology, biology, and treatment. Arch Gen Psychiatry (1998) 4.83
Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med (2001) 4.39
Altered pituitary-adrenal axis responses to provocative challenge tests in adult survivors of childhood abuse. Am J Psychiatry (2001) 4.36
The role of corticotropin-releasing factor in depression and anxiety disorders. J Endocrinol (1999) 3.10
Physiology and pharmacology of corticotropin-releasing factor. Pharmacol Rev (1991) 3.07
Interactions between BDNF Val66Met polymorphism and early life stress predict brain and arousal pathways to syndromal depression and anxiety. Mol Psychiatry (2009) 2.94
Elevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in depressed patients. Science (1984) 2.83
Role of serotonin in the pathophysiology of depression: focus on the serotonin transporter. Clin Chem (1994) 2.77
Role of serotonergic and noradrenergic systems in the pathophysiology of depression and anxiety disorders. Depress Anxiety (2000) 2.76
Effects of thyroxine as compared with thyroxine plus triiodothyronine in patients with hypothyroidism. N Engl J Med (1999) 2.72
Long-term behavioral and neuroendocrine adaptations to adverse early experience. Prog Brain Res (2000) 2.45
Induction of maternal behavior in virgin rats after intracerebroventricular administration of oxytocin. Proc Natl Acad Sci U S A (1979) 2.43
Persistent elevations of cerebrospinal fluid concentrations of corticotropin-releasing factor in adult nonhuman primates exposed to early-life stressors: implications for the pathophysiology of mood and anxiety disorders. Proc Natl Acad Sci U S A (1996) 2.30
Effects of early adverse experiences on brain structure and function: clinical implications. Biol Psychiatry (2000) 2.27
Oxytocin induces maternal behavior in virgin female rats. Science (1982) 2.23
Elevated CSF corticotropin-releasing factor concentrations in posttraumatic stress disorder. Am J Psychiatry (1997) 2.22
Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. J Pharmacol Exp Ther (1997) 2.16
Higher than normal plasma interleukin-6 concentrations in cancer patients with depression: preliminary findings. Am J Psychiatry (2001) 2.08
Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol Psychiatry (2001) 2.05
Reduced brain serotonin transporter availability in major depression as measured by [123I]-2 beta-carbomethoxy-3 beta-(4-iodophenyl)tropane and single photon emission computed tomography. Biol Psychiatry (1998) 2.03
Psychoneuroendocrinology of depression. Hypothalamic-pituitary-adrenal axis. Psychiatr Clin North Am (1998) 1.85
p-Chlorophenylalanine-induced chemical manifestations of phenylketonuria in rats. Science (1967) 1.82
Lower CSF oxytocin concentrations in women with a history of childhood abuse. Mol Psychiatry (2008) 1.82
Subclinical hypothyroidism: a modifiable risk factor for depression? Am J Psychiatry (1993) 1.78
Exaggerated platelet reactivity in major depression. Am J Psychiatry (1996) 1.72
Depression in patients with cancer. Diagnosis, biology, and treatment. Arch Gen Psychiatry (1995) 1.72
Sertraline and desmethylsertraline in human breast milk and nursing infants. Am J Psychiatry (1997) 1.62
Apolipoprotein E-epsilon 4 frequency in geriatric depression. Biol Psychiatry (1996) 1.56
"Normal pressure" pseudotumor cerebri. J Neuroophthalmol (1996) 1.55
Reduced corticotropin releasing factor binding sites in the frontal cortex of suicide victims. Arch Gen Psychiatry (1988) 1.53
The impact of early adverse experiences on brain systems involved in the pathophysiology of anxiety and affective disorders. Biol Psychiatry (1999) 1.52
Hypercortisolemia and hippocampal changes in depression. Psychiatry Res (1993) 1.52
Effects of sodium valproate on corticotropin-releasing factor systems in rat brain. Neuropsychopharmacology (2001) 1.51
Long-term behavioral effects of repetitive pain in neonatal rat pups. Physiol Behav (1999) 1.51
A hypothesis of thyroid-catecholamine-receptor interaction. Its relevance to affective illness. Arch Gen Psychiatry (1981) 1.49
Paroxetine binding to the rat norepinephrine transporter in vivo. Biol Psychiatry (2000) 1.49
Persistent changes in corticotropin-releasing factor neuronal systems induced by maternal deprivation. Endocrinology (1996) 1.48
The CRF system, stress, depression and anxiety-insights from human genetic studies. Mol Psychiatry (2009) 1.43
Bispectral index monitoring. Anesthesiol Clin North America (2001) 1.42
CSF biochemistries, glucose metabolism, and diurnal activity rhythms in alcoholic, violent offenders, fire setters, and healthy volunteers. Arch Gen Psychiatry (1994) 1.41
Magnetic resonance imaging of the caudate nuclei in depression. Preliminary observations. Arch Gen Psychiatry (1992) 1.41
Novel approach to investigate a source of microbial contamination of central venous catheters. Eur J Clin Microbiol Infect Dis (1997) 1.36
Neurotensin and dopamine interactions. Pharmacol Rev (2001) 1.35
Role of norepinephrine in the pathophysiology and treatment of mood disorders. Biol Psychiatry (1999) 1.35
Effects of thyrotropin-releasing hormone in depression. Lancet (1972) 1.34
The role of early adverse life events in the etiology of depression and posttraumatic stress disorder. Focus on corticotropin-releasing factor. Ann N Y Acad Sci (1997) 1.32
Thyrotropin releasing hormone: enhancement of dopa activity by a hypothalamic hormone. Science (1972) 1.31
Alterations in corticotropin-releasing factor-like immunoreactivity in discrete rat brain regions after acute and chronic stress. J Neurosci (1986) 1.30
Hypothermia and intolerance to cold induced by intracisternal administration of the hypothalamic peptide neurotensin. Nature (1976) 1.29
Single-dose pharmacokinetics of clomiphene citrate in normal volunteers. Fertil Steril (1986) 1.26
A magnetic resonance imaging study of putamen nuclei in major depression. Psychiatry Res (1991) 1.26
Mental changes accompanying thyroid gland dysfunction. A reappraisal using objective psychological measurement. Arch Gen Psychiatry (1969) 1.24
Abnormalities of indoleamines in affective disorders. Arch Gen Psychiatry (1972) 1.20
Neurobiology of posttraumatic stress disorder. Curr Opin Neurobiol (2000) 1.20
Neurobiological effects of childhood abuse: implications for the pathophysiology of depression and anxiety. Arch Womens Ment Health (2003) 1.20
Cognitive therapy and pharmacotherapy for depression. J Consult Clin Psychol (1991) 1.19
Potentiation of antidepressant effects by L-triiodothyronine in tricyclic nonresponders. Am J Psychiatry (1982) 1.19
Hippocampal abnormalities in depression. J Neuropsychiatry Clin Neurosci (1991) 1.19
Corticotropin-releasing factor produces fear-enhancing and behavioral activating effects following infusion into the locus coeruleus. J Neurosci (1990) 1.18
Persistent changes in corticotropin-releasing factor systems due to early life stress: relationship to the pathophysiology of major depression and post-traumatic stress disorder. Psychopharmacol Bull (1997) 1.18
Clinical pharmacokinetics of quetiapine: an atypical antipsychotic. Clin Pharmacokinet (2001) 1.18
Continuous expression of corticotropin-releasing factor in the central nucleus of the amygdala emulates the dysregulation of the stress and reproductive axes. Mol Psychiatry (2008) 1.18
Assessment and treatment of depression in the cancer patient. J Psychosom Res (1998) 1.17
Pituitary size in depression. J Clin Endocrinol Metab (1991) 1.16
Women at risk for postpartum-onset major depression. Am J Obstet Gynecol (1995) 1.15
Neuropeptide concentrations in the cerebrospinal fluid of depressed patients treated with electroconvulsive therapy. Corticotrophin-releasing factor, beta-endorphin and somatostatin. Br J Psychiatry (1991) 1.14
Serum thyrotropin response to thyrotropin-releasing hormone in psychiatric patients: a review. Am J Psychiatry (1982) 1.13
Platelet reactivity in depressed patients treated with paroxetine: preliminary findings. Arch Gen Psychiatry (2000) 1.12
Oxytocin facilitates the sexual receptivity of estrogen-treated female rats. Neuropeptides (1986) 1.12
The role of corticotropin-releasing factor in the pathophysiology of affective and anxiety disorders: laboratory and clinical studies. Ciba Found Symp (1993) 1.11
CSF neurotensin concentrations and antipsychotic treatment in schizophrenia and schizoaffective disorder. Am J Psychiatry (1997) 1.10
On the orthomolecular environment of the mind: orthomolecular theory. Am J Psychiatry (1974) 1.09
Differential functional connectivity within an emotion regulation neural network among individuals resilient and susceptible to the depressogenic effects of early life stress. Psychol Med (2012) 1.08
Borderline hypothyroidism and depression. Annu Rev Med (1995) 1.08
Depression during pregnancy and the puerperium. J Clin Psychiatry (1997) 1.07
Rapid eye movement sleep deprivation modifies expression of long-term potentiation in visual cortex of immature rats. Neuroscience (2002) 1.07
Contemporary management of depression. Am J Med (1994) 1.07
Increased corticotropin-releasing factor concentrations in the bed nucleus of the stria terminalis of anhedonic rats. Eur J Pharmacol (2000) 1.07
Pharmacology of orally administered 9 -tetrahydrocannabinol. Clin Pharmacol Ther (1973) 1.05
Enkephalin action on the mesolimbic system: a dopamine-dependent and a dopamine-independent increase in locomotor activity. J Pharmacol Exp Ther (1983) 1.05
Intravenous injection in man of 9 -tetrahydrocannabinol and 11-OH- 9 -tetrahydrocannabinol. Science (1972) 1.05
Overview of clinically significant adverse reactions to bupropion. J Clin Psychiatry (1983) 1.04
Enhancement of imipramine antidepressant activity by thyroid hormone. Am J Psychiatry (1969) 1.04